Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?

Int J Hematol. 2003 Jan;77(1):93-5. doi: 10.1007/BF02982610.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Benzamides
  • Female
  • Humans
  • Imatinib Mesylate
  • Japan
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Male
  • Middle Aged
  • Piperazines / administration & dosage
  • Piperazines / adverse effects*
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*
  • Retrospective Studies
  • Thrombocytopenia / chemically induced*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate